Your search results

A comprehensive testing solution for the detection of  Thyroid Disorders

The Diasorin Anemia panel includes Vitamin B12 and Folate which are used in conjunction to diagnose megaloblastic, microcytic or pernicious anemias, while ferritin is one of the main tests for iron deficiency and it is the first assessment needed to elucidate the causes of anemia.

As a worldwide diagnostic leader in bone and mineral metabolism, Diasorin offers a comprehensive range of immunoassays for the management of bone and calcium metabolism related diseases. The immunoassays 1 - 84 PTH,  N-TACT PTH, BAP OSTASE, OSTEOCALCIN, FGF 23 round out the Vitamin D Solution.

Complete Vitamin D solution for the diagnosis and management of phosphorus and calcium metabolism pathologies. 25OH vitamin D is recognized as a prohormone, which has multiple roles in maintaining optimal health while the active form 1,25OH vitamin D is recommended in therapeutic regimens for chronic kidney disease patient.

Total automation for the accurate staging of CMV infection.

Total automation for accurate differential diagnosis of the Herpes Simplex Virus.

Total automation for accurate differential diagnosis of Parvovirus B19.

Total automation for accurate differential diagnosis of the Rubella virus.

Total automation for the accurate staging of infection

Total automation for accurate differential diagnosis of the measles virus

Total automation for accurate differential diagnosis of the mumps virus.

Total automation for accurate differential diagnosis of the varicella zoster virus.

Automated CLIA assay for the quantitative determination of alpha-fetoprotein (AFP) in human serum as well as in EDTA and heparinized human plasma or amniotic fluid. The test can be used as an aid for pregnancy monitoring and as an aid during the follow-up of tumor patients.

Automated CLIA assay for the quantitative determination of β2-microglobulin (B2M) in human serum, plasma and urine. This test can be used as an aid in the diagnosis of active rheumatoid arthritis and kidney disease. The test can be used as an aid in the evaluation of the severity and prognosis of certain cancers including multiple myeloma and some lymphomas.

Automated CLIA assay for the quantitative determination of CA 125 antigen in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of patients with primary invasive ovarian carcinoma.

Automated CLIA assay for the quantitative determination of the CA 15-3^® antigen in human serum as well as EDTA and heparinized plasma. The test can be used as an aid during the follow-up of patients with breast carcinoma.

Automated CLIA assay for the quantitative determination of the CA 19-9^™ antigen in human serum as well as EDTA or citrated human plasma. The test can be used as an aid during the follow-up of patients with gastrointestinal tumors.

Automated CLIA assay for the quantitative determination of calcitonin in human serum. The determination of calcitonin is an aid in the diagnosis of calcitonin disorders and in the management of medullary thyroid carcinoma.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

Automated CLIA assay for the quantitative determination of free human prostate-specific antigen (fPSA) in human serum and plasma (EDTA or heparinized). The combined use of free PSA and total PSA is an aid in the discrimination of benign and malignant disease with increased specificity of early detection of prostate cancer.

Automated CLIA assay for the quantitative determination of neuron-specific enolase (NSE) in human serum and CSF. The test can be used as an aid for the management of patients with suspected or diagnosed neuroblastoma or small cell lung carcinoma.

Automated CLIA assay for the quantitative determination of human prostate-specific antigen (PSA) in human serum and plasma (heparinized, EDTA). The combined use of free PSA and total PSA is an aid in the discrimination of benign and malignant disease with increased specificity of early detection of prostate cancer.

Automated CLIA assay for the determination of protein S-100B in human serum and CSF (cerebrospinal fluid). The test can be used as an aid in the diagnosis of malignant melanoma and as an aid of diagnosis and prognosis of traumatic brain injury.

Automated CLIA assay for the quantitative determination of Thymidine Kinase (TK) activity in human serum or EDTA plasma. Determination of serum Thymidine Kinase activity is useful for prognosis and monitoring of patients with hematological malignancies. Assay results should be used in conjunction with other clinical and laboratory data to assist in the diagnosis and management of conditions involving hematologic malignancies.

Automated CLIA assay for the quantitative determination of tissue polypeptide antigen, TPA^®, in human serum. This test can be used an aid in the diagnosis of patients with carcinomas such as lung cancer, breast cancer, bladder cancer and therapy monitoring after tumor surgery or treatment.

 The LIAISON^® Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, as an aid in differentiation of IBD from irritable bowel syndrome (IBS) and as an aid to monitoring IBD.

Chronic pancreatitis can cause maldigestion.  Measuring Pancreatic elastase 1 or fecal elastase 1 (FE-1) in feces allows this condition to be assessed.

Helicobacter pylori is the causative agent of chronic gastritis or inflammation of the stomach lining, duodenal and stomach ulcers, and is associated with an increased risk of stomach cancer. 
Diasorin provides a complete diagnostic solution that include 2 CLIA assays for the detection of antigen and for antibodies for H. pylori.

C. difficile is a major cause of antibiotic-associated diarrhea and colitis. It is the causative agent for most cases of pseudomembranous colitis. These combined tests enable the rapid and efficient diagnosis of Clostridium difficile (C. difficile) infection. DiaSorin’s LIAISON^® C. Difficile Diagnostic Solution provides accurate and timely detection of C. difficile infection, improving patient outcomes and reducing healthcare costs.

 The LIAISON^® Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, as an aid in differentiation of IBD from irritable bowel syndrome (IBS) and as an aid to monitoring IBD.

Helicobacter pylori is the causative agent of chronic gastritis or inflammation of the stomach lining, duodenal and stomach ulcers, and is associated with an increased risk of stomach cancer. 
Diasorin provides a complete diagnostic solution that include 2 CLIA assays for the detection of antigen and for antibodies for H. pylori.

Chronic pancreatitis can cause maldigestion.  Measuring Pancreatic elastase 1 or fecal elastase 1 (FE-1) in feces allows this condition to be assessed.

 The LIAISON^® Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, as an aid in differentiation of IBD from irritable bowel syndrome (IBS) and as an aid to monitoring IBD.

Chronic pancreatitis can cause maldigestion.  Measuring Pancreatic elastase 1 or fecal elastase 1 (FE-1) in feces allows this condition to be assessed.

C. difficile is a major cause of antibiotic-associated diarrhea and colitis. It is the causative agent for most cases of pseudomembranous colitis. These combined tests enable the rapid and efficient diagnosis of Clostridium difficile (C. difficile) infection. DiaSorin’s LIAISON^® C. Difficile Diagnostic Solution provides accurate and timely detection of C. difficile infection, improving patient outcomes and reducing healthcare costs.

Automated CLIA assay for the qualitative determination of Campylobacter antigens in human stool specimens. The determination of Campylobacter is an aid in the diagnosis of gastrointestinal disorders.

Helicobacter pylori is the causative agent of chronic gastritis or inflammation of the stomach lining, duodenal and stomach ulcers, and is associated with an increased risk of stomach cancer. 
Diasorin provides a complete diagnostic solution that include 2 CLIA assays for the detection of antigen and for antibodies for H. pylori.

C. difficile is a major cause of antibiotic-associated diarrhea and colitis. It is the causative agent for most cases of pseudomembranous colitis. These combined tests enable the rapid and efficient diagnosis of Clostridium difficile (C. difficile) infection. DiaSorin’s LIAISON^® C. Difficile Diagnostic Solution provides accurate and timely detection of C. difficile infection, improving patient outcomes and reducing healthcare costs.

Complete Vitamin D solution for the diagnosis and management of phosphorus and calcium metabolism pathologies. 25OH vitamin D is recognized as a prohormone, which has multiple roles in maintaining optimal health while the active form 1,25OH vitamin D is recommended in therapeutic regimens for chronic kidney disease patient.

Fully automated solution for the diagnosis of fertility affecting conditions and hormonal monitoring.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

The Diasorin Anemia panel includes Vitamin B12 and Folate which are used in conjunction to diagnose megaloblastic, microcytic or pernicious anemias, while ferritin is one of the main tests for iron deficiency and it is the first assessment needed to elucidate the causes of anemia.

Automated CLIA assay for the quantitative determination of Thymidine Kinase (TK) activity in human serum or EDTA plasma. Determination of serum Thymidine Kinase activity is useful for prognosis and monitoring of patients with hematological malignancies. Assay results should be used in conjunction with other clinical and laboratory data to assist in the diagnosis and management of conditions involving hematologic malignancies.

Fully automated solution for the diagnosis of fertility affecting conditions and hormonal monitoring.

Automated CLIA assay for the quantitative determination of alpha-fetoprotein (AFP) in human serum as well as in EDTA and heparinized human plasma or amniotic fluid. The test can be used as an aid for pregnancy monitoring and as an aid during the follow-up of tumor patients.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

Automated CLIA assay for the quantitative determination of tissue polypeptide antigen, TPA^®, in human serum. This test can be used an aid in the diagnosis of patients with carcinomas such as lung cancer, breast cancer, bladder cancer and therapy monitoring after tumor surgery or treatment.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

Automated CLIA assay for the quantitative determination of tissue polypeptide antigen, TPA^®, in human serum. This test can be used an aid in the diagnosis of patients with carcinomas such as lung cancer, breast cancer, bladder cancer and therapy monitoring after tumor surgery or treatment.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

Automated CLIA assay for the quantitative determination of tissue polypeptide antigen, TPA^®, in human serum. This test can be used an aid in the diagnosis of patients with carcinomas such as lung cancer, breast cancer, bladder cancer and therapy monitoring after tumor surgery or treatment.

As a worldwide diagnostic leader in bone and mineral metabolism, Diasorin offers a comprehensive range of immunoassays for the management of bone and calcium metabolism related diseases. The immunoassays 1 - 84 PTH,  N-TACT PTH, BAP OSTASE, OSTEOCALCIN, FGF 23 round out the Vitamin D Solution.

Chronic pancreatitis can cause maldigestion.  Measuring Pancreatic elastase 1 or fecal elastase 1 (FE-1) in feces allows this condition to be assessed.

Helicobacter pylori is the causative agent of chronic gastritis or inflammation of the stomach lining, duodenal and stomach ulcers, and is associated with an increased risk of stomach cancer. 
Diasorin provides a complete diagnostic solution that include 2 CLIA assays for the detection of antigen and for antibodies for H. pylori.

C. difficile is a major cause of antibiotic-associated diarrhea and colitis. It is the causative agent for most cases of pseudomembranous colitis. These combined tests enable the rapid and efficient diagnosis of Clostridium difficile (C. difficile) infection. DiaSorin’s LIAISON^® C. Difficile Diagnostic Solution provides accurate and timely detection of C. difficile infection, improving patient outcomes and reducing healthcare costs.

The DiaSorin LIAISON^® Q.S.E.T. Device Plus (Quantitative Stool Extraction and Test) is intended for use in the preparation of human stool specimens for testing in designated DiaSorin stool assays.

 The LIAISON^® Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, as an aid in differentiation of IBD from irritable bowel syndrome (IBS) and as an aid to monitoring IBD.

Helicobacter pylori is the causative agent of chronic gastritis or inflammation of the stomach lining, duodenal and stomach ulcers, and is associated with an increased risk of stomach cancer. 
Diasorin provides a complete diagnostic solution that include 2 CLIA assays for the detection of antigen and for antibodies for H. pylori.

C. difficile is a major cause of antibiotic-associated diarrhea and colitis. It is the causative agent for most cases of pseudomembranous colitis. These combined tests enable the rapid and efficient diagnosis of Clostridium difficile (C. difficile) infection. DiaSorin’s LIAISON^® C. Difficile Diagnostic Solution provides accurate and timely detection of C. difficile infection, improving patient outcomes and reducing healthcare costs.

A comprehensive testing solution for the detection of  Thyroid Disorders

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

A comprehensive testing solution for the detection of  Thyroid Disorders

Automated CLIA assay for the quantitative determination of tissue polypeptide antigen, TPA^®, in human serum. This test can be used an aid in the diagnosis of patients with carcinomas such as lung cancer, breast cancer, bladder cancer and therapy monitoring after tumor surgery or treatment.

Automated CLIA assay for the quantitative determination of calcitonin in human serum. The determination of calcitonin is an aid in the diagnosis of calcitonin disorders and in the management of medullary thyroid carcinoma.

Automated CLIA assay for the quantitative determination of neuron-specific enolase (NSE) in human serum and CSF. The test can be used as an aid for the management of patients with suspected or diagnosed neuroblastoma or small cell lung carcinoma.

Automated CLIA assay for the quantitative determination of human prostate-specific antigen (PSA) in human serum and plasma (heparinized, EDTA). The combined use of free PSA and total PSA is an aid in the discrimination of benign and malignant disease with increased specificity of early detection of prostate cancer.

Automated CLIA assay for the determination of protein S-100B in human serum and CSF (cerebrospinal fluid). The test can be used as an aid in the diagnosis of malignant melanoma and as an aid of diagnosis and prognosis of traumatic brain injury.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

Automated CLIA assay for the quantitative determination of tissue polypeptide antigen, TPA^®, in human serum. This test can be used an aid in the diagnosis of patients with carcinomas such as lung cancer, breast cancer, bladder cancer and therapy monitoring after tumor surgery or treatment.

Automated CLIA assay for the quantitative determination of free human prostate-specific antigen (fPSA) in human serum and plasma (EDTA or heparinized). The combined use of free PSA and total PSA is an aid in the discrimination of benign and malignant disease with increased specificity of early detection of prostate cancer.

Automated CLIA assay for the quantitative determination of neuron-specific enolase (NSE) in human serum and CSF. The test can be used as an aid for the management of patients with suspected or diagnosed neuroblastoma or small cell lung carcinoma.

Automated CLIA assay for the quantitative determination of β2-microglobulin (B2M) in human serum, plasma and urine. This test can be used as an aid in the diagnosis of active rheumatoid arthritis and kidney disease. The test can be used as an aid in the evaluation of the severity and prognosis of certain cancers including multiple myeloma and some lymphomas.

The Diasorin Anemia panel includes Vitamin B12 and Folate which are used in conjunction to diagnose megaloblastic, microcytic or pernicious anemias, while ferritin is one of the main tests for iron deficiency and it is the first assessment needed to elucidate the causes of anemia.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

Automated CLIA assay for the quantitative determination of neuron-specific enolase (NSE) in human serum and CSF. The test can be used as an aid for the management of patients with suspected or diagnosed neuroblastoma or small cell lung carcinoma.

Automated CLIA assay for the quantitative determination of CA 125 antigen in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of patients with primary invasive ovarian carcinoma.

Automated CLIA assay for the quantitative determination of the CA 15-3^® antigen in human serum as well as EDTA and heparinized plasma. The test can be used as an aid during the follow-up of patients with breast carcinoma.

Automated CLIA assay for the quantitative determination of the CA 19-9^™ antigen in human serum as well as EDTA or citrated human plasma. The test can be used as an aid during the follow-up of patients with gastrointestinal tumors.